A selective BCL2 inhibitor (venetoclax) was evaluated in 106 patients with relapsed or refractory B cell NHL (i.e. FL, DLBCL, and MCL) as a single agent for its activity and safety profile; however, future studies are needed maximize the therapeutic benefits for these patients (Davids et al., 2017). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.